AI Assistant
Blog
Pricing
Log In
Sign Up
First-Line-Therapie des fortgeschrittenen NSCLC – Bevacizumab plus Cisplatin/Gemcitabin in der INNOVATIONS-Studie hoch wirksam
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.